Publicaciones en las que colabora con Marta Gorraiz Ayala (18)

2023

  1. Local delivery of optimized nanobodies targeting the PD-1/PD-L1 axis with a self-amplifying RNA viral vector induces potent antitumor responses

    Cancer Letters, Vol. 561

2022

  1. Overcoming T cell dysfunction in acidic pH to enhance adoptive T cell transfer immunotherapy

    OncoImmunology, Vol. 11, Núm. 1

  2. TCR-induced FOXP3 expression by CD8+ T cells impairs their anti-tumor activity

    Cancer Letters, Vol. 528, pp. 45-58

  3. Targeting the extra domain A of fibronectin for cancer therapy with CAR-T cells

    Journal for ImmunoTherapy of Cancer, Vol. 10, Núm. 8

2021

  1. Intratumoral STING Agonist Injection Combined with Irreversible Electroporation Delays Tumor Growth in a Model of Hepatocarcinoma

    BioMed Research International, Vol. 2021

  2. Searching for peptide inhibitors of t regulatory cell activity by targeting specific domains of foxp3 transcription factor

    Biomedicines, Vol. 9, Núm. 2, pp. 1-20

2019

  1. Genetic Modification of CD8+ T Cells to Express EGFR: Potential Application for Adoptive T Cell Therapies

    Frontiers in Immunology, Vol. 10

  2. Short-Term Local Expression of a PD-L1 Blocking Antibody from a Self-Replicating RNA Vector Induces Potent Antitumor Responses

    Molecular Therapy, Vol. 27, Núm. 11, pp. 1892-1905

  3. Therapeutic Effect of Irreversible Electroporation in Combination with Poly-ICLC Adjuvant in Preclinical Models of Hepatocellular Carcinoma

    Journal of Vascular and Interventional Radiology, Vol. 30, Núm. 7, pp. 1098-1105

2018

  1. Immunomodulatory properties of carvone inhalation and its effects on contextual fear memory in mice

    Frontiers in Immunology, Vol. 9, Núm. JAN

2017

  1. Blockage of FOXP3 transcription factor dimerization and FOXP3/AML1 interaction inhibits T regulatory cell activity: sequence optimization of a peptide inhibitor

    Oncotarget, Vol. 8, Núm. 42, pp. 71709-71724

2015

  1. Inhibition of FOXP3/NFAT interaction enhances T cell function after TCR stimulation

    Journal of Immunology, Vol. 195, Núm. 7, pp. 3180-3189

2013

  1. A fusion protein between streptavidin and the endogenous tlr4 ligand EDA targets biotinylated antigens to dendritic cells and induces t cell responses in vivo

    BioMed Research International, Vol. 2013

2009

  1. Immunization against hepatitis C virus with a fusion protein containing the extra domain A from fibronectin and the hepatitis C virus NS3 protein

    Journal of Hepatology, Vol. 51, Núm. 3, pp. 520-527

2007

  1. The extra domain A from fibronectin targets antigens to TLR4-expressing cells and induces cytotoxic T cell responses in vivo

    Journal of Immunology, Vol. 178, Núm. 2, pp. 748-756

2005

  1. Enhancement of CD4 and CD8 immunity by anti-CD137 (4-1BB) monoclonal antibodies during hepatitis C vaccination with recombinant adenovirus

    Vaccine, Vol. 23, Núm. 27, pp. 3493-3499

2003

  1. A recombinant adenovirus encoding hepatitis C virus core and E1 proteins protects mice against cytokine-induced liver damage

    Hepatology, Vol. 37, Núm. 2, pp. 461-470

2002

  1. Vaccination with an adenoviral vector encoding hepatitis C virus (HCV) NS3 protein protects against infection with HCV-recombinant vaccinia virus

    Vaccine, Vol. 21, Núm. 3-4, pp. 202-210